Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma.
|
31723000 |
2020 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment.
|
31040671 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival.
|
30680510 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bevacizumab, a VEGF-targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma.
|
30414187 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1.
|
30736462 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, however, BIG1 and BIG2 knockdown significantly decreased the levels of VEGF mRNA and protein in glioblastoma U251 cells and HUVECs.
|
31199673 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the results suggest that the recurrence of GBM is associated with high gene expression levels VEGFA and CXCL8, and the development of the central nervous system.
|
31788092 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using three glioblastoma cell-lines (U87, U251, and SNB19), the adaptation of glioblastoma cells in a 1% (hypoxia) and 20% (normoxia) oxygen microenvironment on proliferation, metabolism, migration, neurosphere formation, CD133 and VEGF expression was investigated.
|
31035344 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.
|
30718358 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, while under normoxic conditions, EGF stimulates the activation of both the PI3K and the MAPK pathways and the induction of VEGF, in glioblastoma cells, hypoxic conditions lead to the suppression of the PI3K/RhoA/C pathway and an exclusive switch to the MAPK pathway.
|
31698752 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Given that VEGF is a modulator of the innate immune response we sought to analyze the dynamics of this response in a mouse model of GBM undergoing anti-VEGF therapy.
|
31660979 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Proangiogenic cytokines such as VEGF and angiopoietin-2 (Ang-2) have high expression in glioblastoma in a cell-specific manner and not only drive tumor angiogenesis and vascular permeability but also negatively regulate T-lymphocyte and innate immune cell responses.
|
31597643 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, we evaluated modular peptide carrier L1 bearing CXCR4 targeting ligand for its ability to condense siRNA and facilitate endosomal escape and VEGFA gene silencing in CXCR4-expressing endothelial and glioblastoma cells.
|
31098995 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME.
|
31713115 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF blockade is still widely used as salvage therapy for recurrent GBM, therefore these intriguing results have potential translational implications as they point to a potential new strategy to overcome VEGF blockade resistance; however, they also raise important questions for the clinical translation of this strategy, and its impact on antitumor responses, in particular immune responses.<i>See related article by Mastrella et al., p. 2298</i>.
|
31043429 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, stellettin B blocks the expression and secretion of a major proangiogenic factor, vascular endothelial growth factor (VEGF), in glioblastoma cells.
|
30769863 |
2019 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic ablation of interleukin-1 ligands or receptor in mice bearing RCAS/tv-a-induced platelet-derived growth factor B-overexpressing glioblastoma results in reduced oedema and partial restoration of the integrity of the blood-brain barrier, respectively; similar to results obtained with vascular endothelial growth factor neutralization.
|
31665239 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
VM has been considered as one of the reasons that glioblastoma becomes resistant to anti-VEGF therapy.
|
30368528 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As a second line treatment of glioblastomas, the vascular endothelial growth factor (VEGF) antibody bevacizumab is administered in combination with the TOP1 inhibitor irinotecan and glioblastoma cell levels of TIMP-1 could therefore potentially influence the efficacy of such treatment.
|
28963609 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Downregulation of the miR-221/222 cluster diminished the invasion, migration, proliferation, and angiogenesis with reduced protein levels of matrix metalloproteinase-2 (MMP-2), MMP-9, and vascular endothelial growth factor in glioblastoma cells.
|
31106423 |
2019 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach.
|
31554364 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although no effective treatment option is available for recurrent glioblastomas (GBMs), a subset of patients evidently derived clinical benefit from bevacizumab, a monoclonal antibody against vascular endothelial growth factor.
|
29573206 |
2018 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of FAT1, EMT (Snail/LOX/Vimentin/N-cad), stemness (SOX2/OCT4/Nestin/REST) and hypoxia markers (HIF-1α/VEGF/PGK1/CA9) was upregulated in ≥39% of GBM tumors (n = 31) with significant positive correlation (p ≤ 0.05) of the expression of FAT1 with LOX/Vimentin/SOX2/HIF-1α/PGK1/VEGF/CA9.
|
28994107 |
2018 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The VEGF polymorphism rs833061 was strongly associated with increased risk for glioma (odds ratio = 164.85) and glioblastoma (odds ratio = 155.66), confirmed after Bonferroni correction.
|
29584591 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bevacizumab (BEV), a humanized monoclonal antibody that blocks the effects of vascular endothelial growth factor A, has produced impressive response rates for recurrent GB and has been approved as second-line therapy.
|
29950856 |
2018 |